Form 4: CytoDyn Director Ryan Dunlap Receives Stock Option Grant

Director Ryan Dunlap receives a stock option grant for 800,000 shares of CytoDyn Inc. common stock.

Summary

• Ryan Dunlap, a director of CytoDyn Inc., was granted a non-qualified stock option to purchase 800,000 shares of common stock on October 28, 2024.
• The exercise price of the option is $0.13 per share.
• The options vest over time, with 266,664 shares vesting immediately and the remainder vesting in equal monthly installments from October 2024 through May 2025.
• The options expire on October 28, 2034.
• Dunlap also has a power of attorney naming Jacob Lalezari, Mitchell Cohen, Tyler Blok, and Nathan Fox as attorneys-in-fact to execute SEC filings on his behalf.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and aligns the director's interests with shareholders. There are no explicitly negative aspects presented.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry to incentivize performance and align management interests with shareholders.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates